FastWave Medical Gains IRB Approval for its Novel Sola™ Coronary Laser IVL (L-IVL) System

FastWave Medical, an innovative startup specialising in intravascular lithotripsy (IVL), has received Institutional Review Board (IRB) approval to begin a coronary feasibility study using its new laser IVL (L-IVL) system, Sola™. 

The company has partnered with Clinical Accelerator to reach this important stage, which will lead to a planned pivotal trial in the US.

The Sola™ L-IVL system is designed to help doctors treat cardiovascular calcium with durable, rupture-resistant balloon catheters. It features a custom laser energy source that creates precise, circumferential sonic pressure waves. 

This technology offers improved control for operators, allowing safe and effective modification of calcified arteries. FastWave aims to improve treatment outcomes for patients with coronary artery disease through this advanced system.

FastWave’s developments represent a significant step forward in IVL therapy, providing interventionalists with new options to treat complex arterial diseases more precisely and efficiently.